financetom
Business
financetom
/
Business
/
GE T&D gets shareholders' nod to double borrowing limit to Rs 1,000 cr
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GE T&D gets shareholders' nod to double borrowing limit to Rs 1,000 cr
Sep 29, 2020 3:57 AM

GE T&D India, a leading player in the power transmission and distribution business, has received shareholders’ approval to double the borrowing limit to Rs 1,000 crore. As per the notice for the company’s 64thAGM held on Monday, a special resolution was proposed to borrow up to Rs 1,000 crore over and above the aggregate of the paid-up share capital, securities premium and free reserves of the company.

All resolutions proposed in the 64th Annual General Meeting held on September 28, 2020, were approved by requisite majority, the company said in a regulatory filing. According to the 64th AGM notice, due to ongoing COVID-19 pandemic and economic downturn/uncertainty, there is a depletion in liquidity and cash flow within the organisation due to delay in payments by some key customers.

The company continues to pay its supplier as per the due date and continue to incur the monthly fixed expenses. Therefore, this may require the company to avail more credit/ borrowings in coming quarters to manage the cash flow requirement, it explained.

The board at its meeting had approved to borrow money from GE India Industrial Pvt Ltd under cash pooling arrangement (CPA) payable on demand and not exceeding in the aggregate up of Rs 1,000 crore excluding interest in such borrowings. In view of the decrease in retained earnings and increase in limit of borrowing from GE group companies, it is desirable to increase the borrowing powers of the company, it had said.

Therefore, the board had sought to raise the borrowing limit to Rs 1,000 crore through special resolution in the 64th AGM held on Monday. Earlier, the shareholders had approved borrowing of Rs 500 crore over and above the aggregate of paid-up share capital and free reserves of the company in its 58th AGM held on July 23, 2014.

First Published:Sept 29, 2020 12:57 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Silgan's Bid to Acquire Gerresheimer Rejected
Market Chatter: Silgan's Bid to Acquire Gerresheimer Rejected
Apr 17, 2026
06:54 AM EDT, 04/17/2026 (MT Newswires) -- Silgan's ( SLGN ) bid to take over German medical packaging maker Gerresheimer has been rejected, Reuters reported Friday, citing sources familiar with the matter. Talks between the two companies have concluded, the sources reportedly said. Silgan ( SLGN ) made a non-binding offer of 41 euros ($48.36) per share, Reuters previously reported....
Bruker's Division Rolls Out MyGenius PRO Diagnostics System in Europe
Bruker's Division Rolls Out MyGenius PRO Diagnostics System in Europe
Apr 17, 2026
06:53 AM EDT, 04/17/2026 (MT Newswires) -- Bruker's ( BRKR ) Bruker Microbiology & Infection Diagnostics division said Friday it has rolled out molecular diagnostics system MyGenius PRO in Europe. The new diagnostics system is based on polymerase chain reaction, developed to diagnose infectious diseases, according to the division. Bruker Microbiology said the MyGenius PRO system automates the complete workflow...
Lilly's Foundayo hits 1,390 prescriptions in debut week
Lilly's Foundayo hits 1,390 prescriptions in debut week
Apr 17, 2026
April 17 (Reuters) - Eli Lilly's ( LLY ) newly launched obesity pill was prescribed 1,390 times in the U.S. as of the week ended April 10, according to an analyst who cited IQVIA data. Novo Nordisk's oral Wegovy had hit 3,071 U.S. prescriptions in the first four days after its launch on January 5. ...
Lilly's obesity pill Foundayo gets 1,390 prescriptions in debut week
Lilly's obesity pill Foundayo gets 1,390 prescriptions in debut week
Apr 17, 2026
April 17 (Reuters) - Eli Lilly's ( LLY ) newly launched obesity pill was prescribed 1,390 times in the U.S. as of the week ended April 10, according to an analyst who cited IQVIA data. Novo Nordisk's oral Wegovy had hit 3,071 U.S. prescriptions in the first four days after its launch on January 5. Investors have been closely watching...
Copyright 2023-2026 - www.financetom.com All Rights Reserved